V5 Ultimate
Ultimate
PricingResourcesCompany
English (original)العربيةDeutschΕλληνικάEspañolFrançaisItalianoעברית日本語한국어NederlandsPolskiPortuguêsSvenska
Talk to us Log in Start free trial
Food & Beverage
  • Bakery & Confectionery
  • Food Processing
  • Ingredients & Dry Mixes
  • Sausage & Meat Products
  • Produce Packing
  • Pet Food & Pet Supplements
  • Dairy & Chilled Foods
  • Beverages & Liquid Manufacturing
  • Infant Formula
Pharma & Life Sciences
  • Radiopharmaceuticals
  • Pharmaceutical
  • Medical Devices
  • Veterinary Pharmaceuticals
  • Blood & Tissue
  • Diagnostics & IVD Kits
  • Reference Materials & Standards
  • OTC Topical Creams & Gels
Supplements & Personal Care
  • Dietary Supplements
  • Cosmetics & Personal Care
  • Cannabis & Hemp Manufacturing
  • Fragrances & Perfumery
  • Soaps & Personal Hygiene
  • Botanical Extracts & Essential Oils
Chemicals & Materials
  • Plastics & Resins
  • Agricultural Chemicals
  • Specialty & Industrial Chemicals
  • Printing Inks, Pigments & Construction Chemicals
  • Lubricants & Metalworking Fluids
  • Coatings, Adhesives & Sealants
Other Manufacturing
  • Consumer Products
  • Electronics & Electrical Assembly
  • Textiles & Nonwoven
  • Contract Manufacturing & Co-Packing
  • Packaging & Food-Contact Materials
  • Regulated Warehousing & Distribution
Explore all industries
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Why V5? Product & Features
Why V5?Product & Features
  • Warehouse & TraceabilityReceive, store, pick and trace
  • Production & PlanningPlan jobs and guide production
  • Quality & LaboratoryTest, investigate and review
  • Documents & TrainingControl procedures and qualifications
  • Equipment & PerformanceMaintain assets and measure losses
  • Orders & IntegrationsConnect customers, suppliers and systems
  • Outputs & InsightsReports, KPIs and label design
Explore all industries
    • Bakery & Confectionery
    • Food Processing
    • Ingredients & Dry Mixes
    • Sausage & Meat Products
    • Produce Packing
    • Pet Food & Pet Supplements
    • Dairy & Chilled Foods
    • Beverages & Liquid Manufacturing
    • Infant Formula
    • Radiopharmaceuticals
    • Pharmaceutical
    • Medical Devices
    • Veterinary Pharmaceuticals
    • Blood & Tissue
    • Diagnostics & IVD Kits
    • Reference Materials & Standards
    • OTC Topical Creams & Gels
    • Dietary Supplements
    • Cosmetics & Personal Care
    • Cannabis & Hemp Manufacturing
    • Fragrances & Perfumery
    • Soaps & Personal Hygiene
    • Botanical Extracts & Essential Oils
    • Plastics & Resins
    • Agricultural Chemicals
    • Specialty & Industrial Chemicals
    • Printing Inks, Pigments & Construction Chemicals
    • Lubricants & Metalworking Fluids
    • Coatings, Adhesives & Sealants
    • Consumer Products
    • Electronics & Electrical Assembly
    • Textiles & Nonwoven
    • Contract Manufacturing & Co-Packing
    • Packaging & Food-Contact Materials
    • Regulated Warehousing & Distribution
PricingResourcesCompany
Start free trial Log in Talk to us
HomeGlossaryBulk-to-Pack Traceability
Inventory & traceability · The complete guide

Bulk-to-Pack Traceability

In short

Preserve parent-child lot relationships, actual quantities, label versions and disposition across bulk manufacture, packaging and distribution, with separate drug, supplement and food requirements.

4,149 words · ~19 min read
Packaging specialists inspect output beside bulk containers and a packing line
Traceability preserves bulk-to-pack relationships and actual material quantities. Editorial illustration; not a customer photograph.
On this page
  1. 01Trace the transformation from bulk to packaged output
  2. 02Define identifiers and lot boundaries before packaging
  3. 03Record each packaging event as a controlled operation
  4. 04Reconcile material without forcing the numbers to match
  5. 05Work through a two-run cream reconciliation
  6. 06Map the runs, side streams and destinations
  7. 07Retrieve one packaged lot back and one bulk lot forward
  8. 08Preserve label and packaging-material relationships
  9. 09Apply the drug batch-record context accurately
  10. 10Apply the dietary supplement record context separately
  11. 11Understand food transformation and traceability records
  12. 12Separate the food rule from current date and enforcement policy
  13. 13Handle splits, returns and authorized combinations
  14. 14Connect distribution and contain an affected scope
  15. 15Audit the relationship and its evidence
  16. 16Control the interval between manufacture and fill
On this page · 16 sections
  1. 1Trace the transformation from bulk to packaged output
  2. 2Define identifiers and lot boundaries before packaging
  3. 3Record each packaging event as a controlled operation
  4. 4Reconcile material without forcing the numbers to match
  5. 5Work through a two-run cream reconciliation
  6. 6Map the runs, side streams and destinations
  7. 7Retrieve one packaged lot back and one bulk lot forward
  8. 8Preserve label and packaging-material relationships
  9. 9Apply the drug batch-record context accurately
  10. 10Apply the dietary supplement record context separately
  11. 11Understand food transformation and traceability records
  12. 12Separate the food rule from current date and enforcement policy
  13. 13Handle splits, returns and authorized combinations
  14. 14Connect distribution and contain an affected scope
  15. 15Audit the relationship and its evidence
  16. 16Control the interval between manufacture and fill
AI · Explain it for MY operation

How does Bulk-to-Pack Traceability apply to your shop floor?

Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.

Your scale

01Trace the transformation from bulk to packaged output

Bulk-to-pack traceability is the ability to reconstruct how a manufactured bulk batch becomes one or more packaged lots and where the resulting material goes. It preserves relationships across transformation, splitting, combining where permitted, packaging, rejects, samples and distribution. A bulk number written on a carton is useful identification, but it is not the entire evidence chain.

The subject crosses regulatory contexts. Drug batch records under 21 CFR 211.188, dietary supplement batch records under 21 CFR 111.260 and food traceability requirements under 21 CFR Part 1 Subpart S apply differently. Do not describe one generic genealogy diagram as compliance with all three. First determine the product, activity, applicable requirements and the records actually needed.

The implementation objective is clear relationships and quantities with sufficient evidence to reconstruct decisions. This article discusses process design and relevant record requirements without inventing a universal tracking algorithm or claiming a named product performs every function. The sample lot trace and distribution record illustrates a record relationship, not a real customer result or a validated recall exercise.

02Define identifiers and lot boundaries before packaging

Identify the bulk batch, product and applicable revision, then define how packaging lots are assigned. A bulk batch may supply several sizes, label versions or destinations. Packaging-lot identity should preserve its parent relationship rather than overwrite the bulk identity. Conversely, repeated use of the same packaging number for unrelated parents can make the relationship ambiguous.

Define what creates a new lot in the actual process. Changes in bulk source, packaging operation, label, time window or other factors may have significance, but no universal rule in this article assigns a new lot for every such event. The applicable procedures and regulatory context should establish the boundary. Document the basis so personnel do not make inconsistent decisions during production pressure.

Maintain relationships when bulk is transferred into intermediate containers or when a partially used container returns to controlled storage. A new local container identifier should remain connected to the original bulk batch and its quantity history. Container identity, material-lot identity and packaging-lot identity can be different identifiers with different purposes; collapsing them into one field may lose useful information.

03Record each packaging event as a controlled operation

For each packaging run, identify the source bulk, actual quantity supplied, packaging lot, equipment or line, dates, label and packaging materials, relevant checks and output quantities. These are practical design elements; the mandatory contents depend on the applicable rule. Record the actual events rather than only an intended packaging order or a final inventory total.

If a bulk batch is packaged in several runs, retain each run's relationship and relevant status. A second run should not inherit the first run's inspection evidence merely because the parent batch is the same. Distinguish product-quality acceptance of bulk from packaging and labeling acceptance of the output. The applicable authority must decide what evidence supports each release or rejection.

The sample batch packaging record helps examine that downstream evidence. It should not be represented as a universal pharmaceutical batch record or a complete supplement production record. Its purpose is to make fields and relationships readable. Apply the actual firm's approved instructions, specifications and review duties when designing its process.

04Reconcile material without forcing the numbers to match

Quantity reconciliation connects bulk input with packaged output, residual material, samples, rejects, loss and transfers. Define the units and calculation basis. Mass and unit count may require a justified conversion, and net product quantity differs from container tare or packaging count. An unexplained conversion can make a reconciliation appear balanced while concealing a real discrepancy.

Record measured or otherwise appropriately determined actual quantities and their basis. Do not count retained samples both as output and as loss, or count residual bulk again when it enters the next run. Where a quantity is estimated, identify the estimate and its justified method rather than presenting it as a direct measurement. The goal is explainable material accounting, not merely a zero balance.

A discrepancy should lead to assessed investigation and disposition under the applicable process. Changing the input quantity after the event until the arithmetic balances destroys useful evidence. Preserve the original observations and explain corrections. This article supplies no universal acceptable-loss percentage; limits must reflect the product, process and relevant approved instructions.

05Work through a two-run cream reconciliation

This fictional example follows an unnamed generic topical cream. Bulk batch B-482 supplies two separately weighed issues: 64.000 kg to Run A and 54.000 kg to Run B, totaling 118.000 kg. Run A produces packaged lot P-482-A; Run B produces P-482-B. No residual from A is reissued to B. Use this accounting example alongside, not instead of, the separate drug, supplement and food record discussions in this article.

The nominal fill is 50 g per tube. Actual mean net fill is 50.50 g per tube in A and 50.25 g in B. The fictional weighing records sum product mass after subtracting container tare for all filled tubes, including samples and rejects. Each subgroup has the same measured mean as its run in this simplified example. Independent tube counts provide a separate check; the nominal declaration is not the conversion basis.

Quantity or dispositionRun A / P-482-ARun B / P-482-B
Bulk issued64.000 kg54.000 kg
All filled tubes — subtotal of the next three rows1,200 tubes / 60.600 kg1,000 tubes / 50.250 kg
Output excluding samples and rejects1,160 tubes / 58.580 kg; released960 tubes / 48.240 kg; held
Retained/QC samples20 tubes / 1.010 kg: 10 retained, 10 QC16 tubes / 0.804 kg: 8 retained, 8 QC
Rejected filled tubes20 tubes / 1.010 kg24 tubes / 1.206 kg
Residual bulk returned to held storage2.700 kg in RES-A2.500 kg in RES-B
Measured line/vessel loss0.700 kg0.950 kg
Known allocated mass — subtotal, not another disposition64.000 kg53.700 kg
Unexplained difference — not measured loss0.000 kg0.300 kg; cause and destination UNKNOWN

All samples are filled tubes removed from output; there are no separate bulk samples within this example's boundary. Rejects remain filled. Line/vessel loss is separately weighed recovered residue, not an allowance calculated to make the balance close. Samples, rejects, residual bulk and measured loss are mutually exclusive categories. The all-filled and known-allocated rows are checks, not extra quantities to add.

Convert actual filled mass to units

  • Run A: filled-product mass = 64.000 − 2.700 − 0.700 = 60.600 kg. Conversion: 60.600 kg × 1,000 g/kg ÷ 50.50 g/tube = 1,200 tubes. Count check: 1,160 output + 20 samples + 20 rejects = 1,200.
  • Run B: independently measured filled-product mass = 50.250 kg. Conversion: 50.250 kg × 1,000 g/kg ÷ 50.25 g/tube = 1,000 tubes. Count check: 960 output + 16 samples + 24 rejects = 1,000. This conversion does not explain the difference against bulk issued.

A's mass check is 58.580 + 1.010 + 1.010 + 2.700 + 0.700 = 64.000 kg. B's known allocation is 48.240 + 0.804 + 1.206 + 2.500 + 0.950 = 53.700 kg, leaving 54.000 − 53.700 = 0.300 kg unexplained. Across both runs, 117.700 kg is allocated to known categories against 118.000 kg issued. The combined tube count is 2,200: 1,160 released output, 960 held output, 36 samples and 44 rejects.

Preserve the UNKNOWN quantity

Investigation INV-B retains the 0.300 kg difference, the original weighing records and the calculation. Its cause and destination remain UNKNOWN. Escalate it for investigation and scope assessment rather than changing the issue weight, inventing rejected tubes or renaming it normal loss. Showing a difference explicitly is not the same as explaining it.

06Map the runs, side streams and destinations

The timeline matters. In this fictional snapshot, a human quality reviewer documented release of A's 1,160-tube output in decision QD-A before Run B occurred. Shipment SH-A1 sent 700 tubes to Depot North; SH-A2 sent 460 to Depot South. These contain 35.350 kg and 23.230 kg respectively, totaling A's 58.580 kg released output. No released A output remains onsite. B's 960-tube output is held in H-B and has not shipped. Both residual-bulk containers remain held.

After B's discrepancy is detected, INV-B also assesses the common bulk parent and already-shipped P-482-A; A's earlier release does not establish that it is unaffected. Record any subsequent containment and disposition decisions separately from the original release.

B-482: two fills with separate output and side-stream branches
  1. 1
    Bulk B-482118.000 kg issued; no residual reissue between runs.
    • → Run A: 64.000 kg
    • → Run B: 54.000 kg
  2. 2
    Run A1,200 filled tubes; actual mean net fill 50.50 g.
    • → P-482-A: 1,160 output tubes / 58.580 kg
    • → Samples: 20 tubes / 1.010 kg
    • → Rejects: 20 tubes / 1.010 kg
    • → Residual bulk: RES-A / 2.700 kg
    • → Measured loss: 0.700 kg
  3. 3
    Run B1,000 filled tubes; actual mean net fill 50.25 g.
    • → P-482-B: 960 output tubes / 48.240 kg
    • → Samples: 16 tubes / 0.804 kg
    • → Rejects: 24 tubes / 1.206 kg
    • → Residual bulk: RES-B / 2.500 kg
    • → Measured loss: 0.950 kg
    • → UNKNOWN difference: 0.300 kg
  4. 4
    P-482-AOutput released under QD-A before Run B; later scope assessment remains separate.
    • → Depot North: SH-A1 / 700 tubes
    • → Depot South: SH-A2 / 460 tubes
  5. 5
    P-482-BOutput held; no release or shipment recorded.
    • → Hold store H-B: 960 tubes
  6. 6
    Depot NorthExternal destination for P-482-A.
    • 700 tubes / 35.350 kg
    • Shipment SH-A1
  7. 7
    Depot SouthExternal destination for P-482-A.
    • 460 tubes / 23.230 kg
    • Shipment SH-A2
  8. 8
    Hold store H-BOnsite location for P-482-B output only.
    • 960 tubes / 48.240 kg
    • Not distributed
  9. 9
    SamplesSample records preserve the run and packaged-lot links.
    • A: 10 retained + 10 QC tubes
    • B: 8 retained + 8 QC tubes
    • Excluded from released and held output
  10. 10
    RejectsSegregated filled tubes retain their original run and lot identities.
    • A: 20 tubes
    • B: 24 tubes
    • Excluded from output and measured loss
  11. 11
    Residual bulkReturned under hold without reissue.
    • RES-A: 2.700 kg from A
    • RES-B: 2.500 kg from B
    • Both retain parent B-482
  12. 12
    Measured lossSeparate weighed line/vessel residue records.
    • A: 0.700 kg
    • B: 0.950 kg
    • Does not include samples, rejects or the UNKNOWN difference
  13. 13
    UNKNOWN differenceNo physical destination established.
    • Run B: 0.300 kg
    • Escalated in INV-B
    • Scope assessment includes B-482 and both packaged lots
Arrows name the next record or destination. Packaged-lot nodes show output excluding samples and rejects. The UNKNOWN branch represents an accounting gap, not a confirmed material transfer.
A balance is not a release decision

A reconciliation that balances is NOT release. Release/disposition is a human quality decision under applicable rules. Neither a zero difference nor a complete diagram supplies that decision. Use the firm's approved instructions for hold times, acceptable loss, yield criteria, measurement tolerances and any applicable label-reconciliation limits; this example sets none.

07Retrieve one packaged lot back and one bulk lot forward

Start the backward exercise with P-482-B and the forward exercise with B-482. Require supporting records, not just the diagram. The table below states what a record must show to answer this exercise; it is not a universal legal checklist. Capture each supporting document identifier and the relevant entry, together with any missing evidence.

Reviewer questionEvidence needed for this exampleWhat a gap looks like
Back from P-482-B: Which bulk supplied it, and how much?The executed Run B record identifies P-482-B and parent B-482. The issue/transfer record shows 54.000 kg, the supplying container identity, weighing basis and actual transfer entry.Only the intended bulk on an order is available, or the transfer container cannot be connected to B-482.
Back from P-482-B: How do mass and tube count agree?The net-weight record supports 50.250 kg in 1,000 filled tubes and the actual mean of 50.25 g. Output, sample and reject records support the separate 960, 16 and 24 tube categories.The calculation uses nominal 50 g, omits rejects from its basis, or counts sample tubes again within output.
Back from P-482-B: What happened during packaging and holding?The executed record identifies the actual line, packaging-material lots, label revision or specimen, relevant hold/fill timestamps and instruction revision. The hold record identifies H-B and the 960 tubes; sample, reject and RES-B records identify their separate locations and statuses.A current label master replaces historical use evidence, only scheduled times exist, or returned bulk has no container or status record.
Forward from B-482: Are both runs and all branches present?Issue records show 64.000 kg to A and 54.000 kg to B. Run records link both packaged lots. Sample and reject logs account for 36 and 44 tubes respectively; return records show RES-A plus RES-B totaling 5.200 kg, held without reissue.Run B is absent, side streams have no parent link, or returned residual is incorrectly counted as a fresh issue.
Forward from B-482: Where is every output tube?QD-A supports A's historical release. SH-A1 and SH-A2 identify P-482-A, the shipment dates, destinations and 700/460 tube split. H-B supports the location and held status of all 960 P-482-B output tubes.A shipment total lacks a packaged-lot identity, a destination cannot be retrieved, or held output is reported as distributed.
Both directions: Where is the unexplained 0.300 kg recorded, and who is addressing it?INV-B preserves 54.000 kg issued versus 53.700 kg allocated, original observations, escalation, investigation owner and scope assessment covering the parent and both packaged lots.The difference disappears into a loss allowance, an input is overwritten, or A is excluded merely because it previously balanced.
Both directions: Who decided release, hold or other disposition?QD-A identifies the human reviewer, decision, date and supporting evidence. B's hold and any later decisions remain separately identifiable, as do decisions arising from the assessment of shipped A output.A reconciliation total, inventory status or shipment record is treated as the release authorization.

Log unanswered questions as UNKNOWN, with an owner and follow-up action. Distinguish a missing document from an unresolved physical quantity: finding the issue ticket may close a retrieval gap without explaining the 0.300 kg difference. Record actual retrieval time without imposing an invented deadline. The Lot Trace Exercise Worksheet can organize the questions and evidence references.

08Preserve label and packaging-material relationships

Traceability includes more than the bulk product. Label version and packaging-material identity can determine which output is affected by an error. Maintain the relationship between each packaging lot and the materials actually used, including relevant issued, used, rejected and returned quantities. A current label master does not demonstrate which label was applied historically.

For dietary supplements, section 111.260(k) addresses identifiers and quantities of packaging and labels, label reconciliation where required, the actual or representative label or permitted location reference, and relevant examinations or references. Preserve the conditional wording about reconciliation. Do not assume the identical rule applies without qualification to every label and product context.

For drug products, section 211.188 includes complete labeling-control records with specimens or copies of labeling used and other batch-production information. Read that provision alongside other applicable drug GMP requirements. A packaging-material scan alone is not a complete labeling-control record, and a readable sample does not establish that line clearance, issuance or reconciliation requirements have been met.

09Apply the drug batch-record context accurately

Section 211.188 requires batch production and control records for each drug batch, including complete information relating to production and control. Its listed elements include dates, major equipment and lines, component or in-process material batch identification, weights and measures, results of in-process and laboratory controls, inspection of packaging and labeling areas, yields, labeling records, personnel identification and relevant investigations.

Bulk-to-pack relationships help connect those elements across operations, but they do not replace them. A genealogy report can identify which bulk supplied a packaging lot while omitting laboratory results or investigation evidence. Conversely, a signed production record can remain difficult to reconstruct if its packaging references are ambiguous. Assess completeness and relationships separately.

The GMP batch walk follows one fictional batch through the evidence chain. It does not confer product release, validation or GMP compliance. Identify the actual responsible quality function and applicable decision requirements. EU QP certification, where relevant, is a separate subject under EU GMP Annex 16 (EudraLex Volume 4), not an inference from a US batch-record reference.

10Apply the dietary supplement record context separately

Section 111.260(a) identifies the finished-batch number and relevant downstream lot numbers assigned under section 111.415(f), including packaged and labeled lots and lots distributed for packaging or labeling. This supports a clear relationship between production and downstream activity. The BPR also requires actual component use, yield, results, contemporaneous manufacturing and packaging documentation, QC decisions and applicable material reviews.

The batch production record article explains those requirements in their own context. Do not use 'batch packaging record' as an alternative name for the entire supplement BPR. Packaging evidence is only one portion. A bulk acceptance decision does not remove the need for applicable packaging and labeling review and disposition.

Where another organization packages received bulk, define the information exchanged and the responsibilities applicable to each activity. A commercial handoff should not sever the original identity or leave the receiving packer unable to assess the product against applicable requirements. Document actual agreements and evidence availability rather than assuming that the supplier's release resolves every downstream obligation.

11Understand food transformation and traceability records

The FDA Food Traceability Rule establishes additional recordkeeping requirements for persons who manufacture, process, pack or hold foods on the Food Traceability List, subject to the rule's scope and exemptions. It uses critical tracking events and key data elements. A transformation can include relevant manufacturing or processing operations and changes to food or its packaging or packing as described in the rule and FAQs.

For an applicable transformation, preserve the required relationship between incoming traceability lots and the resulting traceability lot, including required quantities and other key data elements. A firm's internal bulk and packaging numbers may support that relationship but are not automatically identical to the rule's traceability lot code. Understand when a code is assigned and how it remains connected to its source.

Do not imply that the rule covers all foods, every movement or every retail activity identically. Determine the Food Traceability List applicability, exemptions and actual tracking events. The Food Processing Operations Guide supplies operational context; the codified rule and current official interpretation establish the legal requirements for the actual operation.

12Separate the food rule from current date and enforcement policy

The FDA rule hub, reviewed 9 October 2026, states the original compliance date was 20 January 2026 and that FDA proposed a 30-month extension to 20 July 2028. It also states that the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act of 2026 directed FDA not to enforce the rule before that same date, and that FDA intends to comply with the Congressional directive.

Those are distinct facts: the codified rule and its original date, a proposed regulatory extension, and a separate Congressional non-enforcement direction. Do not describe the proposed extension as a finalized amendment unless an official final rule is verified. Do not omit the current Congressional enforcement position when explaining practical timing. The FDA hub and updates should be rechecked when an implementation decision is made.

FDA also announced draft enforcement-discretion guidance in October 2026 for certain smaller retail food establishments and restaurants. The draft is not for implementation and should not be presented as a finalized blanket exemption. Its proposed scope is narrower than all retailers. This article does not determine eligibility; it distinguishes a draft policy from the rule's existing exemptions and the separate non-enforcement direction.

13Handle splits, returns and authorized combinations

A split should preserve one parent's relationship to each resulting output and the quantities assigned to them. A return from packaging to bulk storage should retain its source and status, including whether exposure, handling or identification requires assessment. Returned material should not automatically become indistinguishable available stock merely because it physically re-enters the warehouse.

Where combining material is permitted by the applicable process, preserve all parent relationships and the authorized decision. Do not imply that traceability software makes otherwise prohibited mixing acceptable. If a quantity cannot be assigned reliably to a parent, document the uncertainty and assess its effect on the affected scope. An artificial precise allocation is worse than an honestly recorded limitation.

Define how rejected packaging output, rework or repackaging remains connected to the original operation. The new operation should not erase the earlier rejection or create a clean history without the original evidence. Maintain the applicable review and disposition records. These are process-design principles; product-specific rework permissions must come from the actual requirements and approved procedures.

14Connect distribution and contain an affected scope

Trace-forward should identify where the packaged output went, while trace-back identifies relevant bulk and source material. The batch genealogy record checklist helps organize those questions. A report listing only warehouse stock can omit output already shipped, transferred or returned. Define the record boundary and the downstream information needed for the actual activity.

A trace exercise should distinguish identified affected lots from uncertain potentially affected material. Review customers or destinations only using authorized actual data within the organization's controlled process; this article uses no customer examples. A complete genealogy does not by itself decide recall scope, regulatory notification or product safety. Qualified personnel must assess the relevant issue and applicable duties.

For a discrepancy, preserve the initiating issue, evidence reviewed, containment, scope conclusion and subsequent decision. Avoid promising that any system identifies every affected unit instantly or assures recall success. Test the actual process, including inaccessible records and external handoffs, and record observed retrieval performance rather than inventing timing or completeness claims.

15Audit the relationship and its evidence

Select a bulk batch with more than one packaging run and follow it into each output lot, label version, quantity reconciliation and distribution reference. Then select one packaging lot and trace back to all relevant parents. Review a return or repackaging event and confirm the original status and decision remain visible. These evidence paths test whether relationships survive normal complexity.

Ask who assigns lot boundaries, who reconciles quantities, who investigates discrepancies and who authorizes release or rejection. Potential weaknesses include overwritten parent identifiers, packaging lots disconnected from bulk, repeated counting of residual material, label revisions not recorded, unsupported quantity conversions and external handoffs without retrievable evidence. The audit should assess the actual process rather than presume failures.

The traceability feature page, food sector page and linked guides offer further context. They do not establish regulatory conformity, validation or a product capability not independently verified. The responsible organization owns its applicable scope assessment, controlled records and decisions; bulk-to-pack traceability supports those duties but does not replace them.

16Control the interval between manufacture and fill

Bulk may be held before packaging, sometimes through more than one filling operation. Preserve the manufacture time, relevant hold conditions, filling times and the applicable approved limit or assessment. Hold-time suitability is a product-and-process question; a lot relationship alone cannot establish that material remained suitable while awaiting packaging. Different dosage forms and formulations may need different evidence.

For US drug manufacture, section 211.111 addresses time limits for completing production phases where appropriate to assure quality. Departures can be acceptable where they do not compromise quality and are justified and documented. Assess that provision for the actual operation rather than assigning a universal number of hours to every cream, liquid or blend. Packaging and labeling area controls under section 211.130 and label controls under section 211.125 are related but separate requirements.

During split fills, calculate the interval for each run rather than carrying forward the first run's start time as evidence for all later output. Record interruptions and the status of residual bulk. If the approved limit is exceeded, preserve the event and obtain the applicable quality assessment; changing the recorded manufacture time to keep the interval within range would obscure the issue.

Cover of The OTC Topical Manufacturing Guide
For OTC topical creams & gels

Putting Bulk-to-Pack Traceability into practice

It follows one cream batch from the mixing vessel through tube and jar fills, with hold times, fill checks and label reconciliation.

The OTC Topical Manufacturing Guide · 22-page guide

Get the guide See the industry page

Frequently asked questions

Q.Is a bulk-to-pack report a complete batch record?+

Not necessarily. It can show relationships while omitting required production, testing, labeling or decision evidence. Evaluate the complete record requirements for the actual drug, supplement or food context.

Q.Is the food traceability July 2028 date a finalized rule amendment?+

The FDA hub reviewed 9 October 2026 describes a proposed extension and a separate Congressional direction not to enforce before 20 July 2028. Those instruments must not be conflated with a verified final regulatory amendment.

Q.Which fill weight should convert bulk mass into tube count?+

Use the supported actual net fill for the material being counted, not the nominal declaration or gross container weight. In the fictional Run A, 60.600 kg of filled product × 1,000 g/kg ÷ 50.50 g/tube = 1,200 tubes. Do not divide the entire bulk issue by fill weight when part of that issue remains as residual bulk or loss.

Q.Can an unexplained mass difference be entered as normal filling loss?+

Not simply to make the balance close. Run B has 0.950 kg of separately measured loss and a different, unexplained 0.300 kg difference. Preserve that distinction, retain the original observations and escalate the unresolved quantity for investigation and scope assessment.

Q.Does a balanced reconciliation authorize release?+

No. Reconciliation supports review; release/disposition is a human quality decision under applicable rules. Keep the decision, reviewer, date and supporting evidence separate from the arithmetic. Any limits used in the review come from the firm's approved instructions, not this example.

Primary sources

  • 21 CFR 211.188: drug batch production and control records — reviewed 9 Oct 2026
  • 21 CFR 211.111, 211.125 and 211.130: holding and packaging controls — reviewed 9 Oct 2026
  • 21 CFR 111.260 — reviewed 9 Oct 2026
  • FDA Food Traceability Rule current hub and compliance/enforcement distinction — reviewed 9 Oct 2026
  • FDA Food Traceability Rule current FAQs — reviewed 9 Oct 2026
  • FDA proposed compliance-date extension impact analysis — reviewed 9 Oct 2026
  • FDA October 2026 draft small-retailer enforcement policy — reviewed 9 Oct 2026
  • Official published CFR: Part 111, 2025 edition — reviewed 9 Oct 2026

Further reading

  • Sample lot trace and distribution
    Inspect parent-output and destination relationships.
  • Sample batch packaging record
    Connect packaging execution to bulk identity.
  • Batch Genealogy Record Checklist
    Check splits, returns and evidence retrieval.
  • Lot Trace Exercise Worksheet
    Rehearse quantity and destination retrieval across split packaging runs.
Software that covers Bulk-to-Pack Traceability
V5 Ultimate (GMP)
V5 Ultimate is a full-lifecycle GMP platform for US and international manufacturers — cGMP under 21 CFR 210/211, EU GMP Parts…
Talk to us about Bulk-to-Pack Traceability

Want to see how Bulk-to-Pack Traceability could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.

Start free
Back to glossary
Where this term comes up
PharmaceuticalCosmeticsDietary SupplementsOTC Topicals
Inside V5
  • → Lot traceability — recall in minutes, not weeks.
  • → Production — run the work order, record it as it happens.
  • → Labels — designed, approved, checked and printed in one place.
Example reports
V5Ultimate

Sample report

Work Order Traveler

Plan & make

Work Order TravelerView on screen or print
V5Ultimate

Sample report

Batch Packaging Record (packaging stage)

Plan & make

Batch Packaging Record (packaging stage)View on screen or print
→ All example reports
Regulatory anchors
  • 21 CFR 211.111
  • 21 CFR 211.125
  • 21 CFR 211.130
  • 21 CFR 211.188
Related terms
  • → OTC Monograph
  • → 21 CFR 210
  • → Quality Agreement

Next Step

Try V5 with your own records, or ask a question first. Ask V5 opens with an editable question; nothing is sent until you choose to.

Start your free trial Browse All Features

Showing the site for the United States. Local spelling, dates and prices are applied automatically; change the language at the top of the page.

V5 Ultimate
Ultimate

Warehouse, quality and manufacturing software for regulated operations.

ProductIndustriesPricingResourcesSecurity & TrustCompanyLegal Centre

© S.G. Systems, LLC